Published in Cancer Metastasis Rev on October 12, 1999
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene (2009) 1.29
Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res (2006) 0.99
New horizons in prostate cancer imaging. Eur J Radiol (2008) 0.99
Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers. Neoplasia (2007) 0.92
Altered differentiation and proliferation of prostate epithelium in mice lacking the androgen receptor cofactor p44/WDR77. Endocrinology (2010) 0.87
Structure-based virtual screening and identification of a novel androgen receptor antagonist. J Biol Chem (2012) 0.80
Loss of the androgen receptor cofactor p44/WDR77 induces astrogliosis. Mol Cell Biol (2012) 0.76
Male pattern baldness and risk of colorectal neoplasia. Br J Cancer (2016) 0.75
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (1997) 4.56
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene (1996) 2.17
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A (2007) 2.11
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A (1995) 2.10
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol (1999) 1.56
Differential complementation of Bcr-Abl point mutants with c-Myc. Science (1994) 1.52
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res (2001) 1.46
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem (1996) 1.33
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol (2000) 1.31
Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta (1997) 1.20
Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program (2001) 1.16
p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase. Oncogene (1995) 1.15
Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer (2001) 1.11
Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Mol Cell Biol (1998) 1.09
A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis (1986) 1.01
c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency. Proc Natl Acad Sci U S A (2000) 0.89
Research on resistance to cancer drug Gleevec. Science (2001) 0.86
Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. J Natl Cancer Inst (1998) 0.85
Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer. Curr Opin Investig Drugs (2001) 0.84
Functional role for the c-Abl tyrosine kinase in meiosis I. Oncogene (1998) 0.83
Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination. Proc Natl Acad Sci U S A (1994) 0.75
Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL. Cold Spring Harb Symp Quant Biol (1994) 0.75
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice. Int J Cancer (1994) 0.75
Signal transduction-based strategies for the treatment of chronic myelogenous leukemia. Mol Med Today (1996) 0.75